Trending Stock News

DENTSPLY SIRONA Inc. (XRAY) EPS Estimated At $0.81; Vanda Pharmaceuticals Inc. (VNDA) Had 7 Bullish Analysts

Analysts expect DENTSPLY SIRONA Inc. (NASDAQ:XRAY) to report $0.81 EPS on February, 16.They anticipate $0.14 EPS change or 20.90% from last quarter’s $0.67 EPS. XRAY’s profit would be $186.05 million giving it 19.11 P/E if the $0.81 EPS is correct. After having $0.70 EPS previously, DENTSPLY SIRONA Inc.’s analysts see 15.71% EPS growth. The stock decreased 0.64% or $0.4 during the last trading session, reaching $61.91. About 499,367 shares traded. DENTSPLY SIRONA Inc. (NASDAQ:XRAY) has risen 2.17% since January 19, 2017 and is uptrending. It has underperformed by 14.53% the S&P500.

Among 7 analysts covering Vanda Pharmaceuticals (NASDAQ:VNDA), 7 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Vanda Pharmaceuticals had 20 analyst reports since September 2, 2015 according to SRatingsIntel. The firm has “Buy” rating by Oppenheimer given on Sunday, November 12. On Friday, August 26 the stock rating was maintained by JMP Securities with “Market Outperform”. Jefferies maintained the stock with “Buy” rating in Monday, June 26 report. Jefferies reinitiated the stock with “Buy” rating in Thursday, October 6 report. The firm earned “Outperform” rating on Monday, October 30 by Oppenheimer. The firm has “Buy” rating given on Wednesday, November 9 by Aegis Capital. JMP Securities maintained Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) rating on Wednesday, March 9. JMP Securities has “Market Outperform” rating and $18 target. The company was maintained on Thursday, August 3 by H.C. Wainwright. The firm has “Buy” rating given on Monday, January 8 by Oppenheimer. Piper Jaffray initiated the shares of VNDA in report on Tuesday, June 27 with “Buy” rating. See Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) latest ratings:

08/01/2018 Broker: Oppenheimer Rating: Buy Maintain
12/11/2017 Broker: Oppenheimer Rating: Buy New Target: $25.0 Maintain
30/10/2017 Broker: Oppenheimer Rating: Outperform Old Target: $21 New Target: $26 Maintain
19/10/2017 Broker: Piper Jaffray Rating: Buy New Target: $26.0 Maintain
04/09/2017 Broker: Jefferies Rating: Buy New Target: $21.0 Maintain
01/09/2017 Broker: JMP Securities Rating: Buy New Target: $24.0
03/08/2017 Broker: Piper Jaffray Rating: Buy New Target: $23.0000 Maintain
03/08/2017 Broker: H.C. Wainwright Rating: Buy New Target: $18.0000 Maintain
03/08/2017 Broker: Oppenheimer Rating: Buy New Target: $21.0000 Maintain

Investors sentiment increased to Infinity in 2017 Q3. Its up Infinity, from 4 in 2017Q2. It improved, as 0 investors sold DENTSPLY SIRONA Inc. shares while 0 reduced holdings. 1 funds opened positions while 5 raised stakes. 812,996 shares or 4.27% more from 779,672 shares in 2017Q2 were reported. 252 are held by Gemmer Asset Management Ltd. Eqis Cap Mngmt accumulated 6,182 shares or 0.02% of the stock. West Oak Cap Llc owns 23,114 shares for 0.82% of their portfolio. Tirschwell & Loewy Inc invested in 248,398 shares or 2.25% of the stock. Cibc holds 52,357 shares or 0.03% of its portfolio. Burney holds 3,651 shares. Cardinal Capital Management holds 1.37% or 72,544 shares.

Since January 8, 2018, it had 0 buys, and 1 sale for $436,068 activity. 6,409 DENTSPLY SIRONA Inc. (NASDAQ:XRAY) shares with value of $436,068 were sold by BRANDT ERIC.

DENTSPLY SIRONA Inc. designs, develops, makes, and markets various dental and oral health products, and other consumable healthcare products primarily for the professional dental market worldwide. The company has market cap of $14.22 billion. It operates through two divisions, Dental and Healthcare Consumables; and Technologies. It currently has negative earnings. The firm provides dental consumable products, including endodontic instruments and materials, dental anesthetics, prophylaxis pastes, dental sealants, impression materials, restorative materials, tooth whiteners, and topical fluoride products; and small equipment products comprising dental hand pieces, intraoral curing light systems, dental diagnostic systems, and ultrasonic scalers and polishers.

Among 19 analysts covering Dentsply International (NASDAQ:XRAY), 13 have Buy rating, 1 Sell and 5 Hold. Therefore 68% are positive. Dentsply International had 49 analyst reports since August 3, 2015 according to SRatingsIntel. Zacks downgraded the stock to “Hold” rating in Thursday, September 3 report. William Blair upgraded DENTSPLY SIRONA Inc. (NASDAQ:XRAY) on Monday, September 21 to “Outperform” rating. Northcoast upgraded DENTSPLY SIRONA Inc. (NASDAQ:XRAY) on Friday, September 18 to “Buy” rating. Deutsche Bank initiated DENTSPLY SIRONA Inc. (NASDAQ:XRAY) on Friday, December 8 with “Buy” rating. The stock has “Buy” rating by Robert W. Baird on Friday, September 15. The stock of DENTSPLY SIRONA Inc. (NASDAQ:XRAY) has “Sell” rating given on Tuesday, May 23 by Goldman Sachs. Robert W. Baird maintained it with “Buy” rating and $63.0 target in Thursday, October 19 report. The stock of DENTSPLY SIRONA Inc. (NASDAQ:XRAY) earned “Outperform” rating by Robert W. Baird on Wednesday, September 16. Stifel Nicolaus maintained DENTSPLY SIRONA Inc. (NASDAQ:XRAY) rating on Wednesday, August 9. Stifel Nicolaus has “Buy” rating and $7000 target. Piper Jaffray initiated the stock with “Overweight” rating in Monday, June 13 report.

The stock increased 1.58% or $0.225 during the last trading session, reaching $14.475. About 107,499 shares traded. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has risen 51.60% since January 19, 2017 and is uptrending. It has outperformed by 34.90% the S&P500.

Investors sentiment increased to 1.43 in 2017 Q3. Its up 0.26, from 1.17 in 2017Q2. It is positive, as 12 investors sold Vanda Pharmaceuticals Inc. shares while 34 reduced holdings. 21 funds opened positions while 45 raised stakes. 38.89 million shares or 4.39% more from 37.25 million shares in 2017Q2 were reported. Axiom Ltd Liability Corp De reported 137,167 shares. Tudor Invest Et Al reported 0.01% in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Legal & General Grp Public Ltd Liability holds 0% in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) or 12,663 shares. Principal Grp Incorporated stated it has 0% in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Cheyne Management (Uk) Llp owns 24,000 shares for 0.48% of their portfolio. Schwab Charles Mngmt Incorporated has 0.01% invested in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Baker Bros Lp accumulated 0.06% or 423,884 shares. Citigroup Inc reported 0% stake. Vanguard Group Inc Inc holds 2.77M shares. Bnp Paribas Arbitrage stated it has 0% of its portfolio in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Kopp Inv Advsr Llc owns 12,020 shares for 0.2% of their portfolio. Massachusetts Financial Ma has 0% invested in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) for 10,967 shares. Goldman Sachs Group Inc invested in 0% or 426,108 shares. Parametric Portfolio Assocs Ltd Liability Corp reported 65,576 shares. Balyasny Asset Limited Liability Corp reported 21,900 shares.

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company has market cap of $650.33 million. The companyÂ’s marketed products include HETLIOZ , a product for the treatment of non-24-hour sleep-wake disorder; and Fanapt (iloperidone), a product for the treatment of schizophrenia. It currently has negative earnings. The Company’s clinical development products include Tradipitant (VLY-686), a small molecule neurokinin-1 receptor antagonist that is under the clinical development for the treatment of chronic pruritus in atopic dermatitis and gastroparesis; Trichostatin A, a small molecule histone deacetylase inhibitor, which is in development for the treatment of hematologic malignancies; and AQW051, a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist.

Since January 2, 2018, it had 0 insider buys, and 4 sales for $3.36 million activity. 191,760 shares valued at $2.93M were sold by Polymeropoulos Mihael Hristos on Tuesday, January 2. $130,777 worth of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) was sold by Birznieks Gunther on Tuesday, January 2. $140,494 worth of stock was sold by Kelly James Patrick on Tuesday, January 2. 10,367 Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) shares with value of $157,565 were sold by Gulino Richard L..

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Leave a Reply

Your email address will not be published. Required fields are marked *